FRISS
13.6.2019 07:02:06 CEST | Business Wire | Press release
Eurolife ERB, a Fairfax company, has won the IMPACT BITE (Business IT Excellence) Awards 2019 in the category IT Business Process Improvement, for its AI approach to assess risks and reduce the likelihood of fraud. The IMPACT Bite Awards is open to all companies, across industries, who have successfully integrated IT & tech systems and/or have taken initiatives in the domains of IT & Comms infrastructure that support their business goals. Eurolife ERB entered the competition with their successful implementation of the FRISS solution for automated fraud prevention. Thanks to this solution they lowered their loss ratio, enabled digital transformation and improved their customer experience.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190612005694/en/
Eurolife ERB, a leading player in the Greek insurance market, has the goal to reduce the risk it faces in cases of fraud involving future indemnities in the car insurance industry. Through the use of Artificial Intelligence, Eurolife ERB, in close cooperation with FRISS, has created a process of automated, more detailed risk assessment control, seeking faster, more complete and safer processing. This provides them with better customer service while contributing significantly to maintaining a net portfolio.
John Kostoglou, CIO of Eurolife ERB: “I’m very proud that we have won this award. It is great to see that our focus on innovation and digital transformation get recognized. For every insurance company the possibility of fraud is very high, in particular for contracts relating to the car industry. With the help of FRISS we are able to detect high risks and fraud in real-time. With this state-of-the art technology we save time and money for our customers.”
Simon Staadegaard, Sales Manager at FRISS, states: “We are delighted to see that our efforts to detect fraud and support honest insurance pay off. The recognition by IMPACT shows that the insurance industry really values the power of our AI solutions that are combined with our expert industry knowledge. The project with Eurolife ERB went smoothly. It was delivered on time and within budget. We look forward to a bright and fraud free future together.”
About Eurolife ERB
Eurolife ERB Insurance Group is a member of Fairfax Financial Holdings Ltd., who, through its subsidiaries, operates in insurances, reinsurance and investments’ management. Eurolife ERB Insurance Group, through its subsidiaries in Greece and Romania, designs, markets and promotes advanced products and services that meet the full range of contemporary insurance needs. Group companies in Greece include Eurolife ERB Life Insurance SA, Eurolife ERB General Insurance SA and ERB Insurance Brokers SA. A leading player in the bancassurance market, the Group has established a broad network of affiliated insurance agents across Greece. Group companies in Romania include Eurolife ERB Asigurari de Viata and Eurolife ERB Asigurari Generale. Eurolife ERB Insurance Group consistently maintains strong earnings levels and capital reserves in excess of European regulatory requirements, so as to always fulfil its responsibilities towards its clientele. Understanding its role in the society, Eurolife ERB Insurance Group is committed to give back to the communities a part of its profits per year. Through its corporate social responsibility program, the Group implements actions: (a) for quality of life and wellness, (b) for the promotion of education and culture, (c) for entrepreneurship and economy, supporting more choices and optimism for the future.
For more information, visit eurolife.gr
About FRISS
FRISS has a 100% focus on automated fraud and risk detection for P&C insurance companies worldwide. The AI-powered detection solutions for underwriting, claims and SIU have already helped 150+ insurers to grow their business. FRISS detects fraud, mitigates risks and supports digital transformation. Insurers go live within 6 months, with fixed price projects, and realize an ROI within 12 months. The FRISS solutions help to lower the loss ratio, enable profitable portfolio growth, and improve the customer experience. www.friss.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20190612005694/en/
Contact:
Ruud van Gerwen PR & Product Marketer at FRISS +31 30 767 0352 Ruud.van.gerwen@friss.com
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release
Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom